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Abstract 
Introduction: This study presents a 10-year longitudinal assessment of bone status in adolescents and young adults with type 1 diabetes 
(T1D).
Material and methods: Thirty-two patients (12 female, aged 20.5 ± 3.93 years, T1D duration 13.9 ± 1.97 years) were studied using quanti-
tative ultrasound (QUS) and dual-energy X-ray absorptiometry (DXA). Standard deviation scores (SDS) for these results were calculated. 
The following clinical parameters were analysed: sex, age, T1D duration, anthropometric parameters, daily insulin requirement (DIR), 
mean glycated haemoglobin (HbA1c) in the year preceding the examination, medication other than insulin, history of bone fractures, and 
comorbidities.
Results: The current and past (measured 10 years earlier) QUS results did not differ and showed a significant correlation (r = 0.55, 
p = 0.001). We found no relation of QUS results and anthropometric parameters or gender. DXA parameters did not correlate with the 
present QUS measurement. DXA and QUS results were independent of HbA1c, co-morbidities, or intake of additional medicaments.
Conclusions: Bone status parameters of the examined patients with currently suboptimal glycaemic control were found to be lowered in 
comparison to a normative reference population, both at baseline and follow-up, although no further deterioration was observed during 
the 10-year follow-up period. (Endokrynol Pol 2020; 71 (6): 532–538)
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Introduction
Bone mass in children and adolescents is highly depen-
dent on environmental and hormonal factors. During 
this critical period of the skeleton’s development, the 
majority of type 1 diabetes (T1D) cases are diagnosed. 
In the last decades, several studies concerning the 
influence of type 2 as well as type 1 diabetes on bone 
were published [1, 2]. The pathomechanism of the 
development of bone changes includes factors like in-
sulinopaenia, deficiency of growth hormone and factors 
(e.g. insulin-like growth factor IGF-1), hypercalciuria 
associated with glucosuria, improper collagen I syn-
thesis [3], as well as advanced glycation end products 
(AGEs) accumulating likewise in bones [4]. It has been 
suggested that bone disease might be another manifes-
tation of microvascular disease in T1D [1].
The results of some previously performed studies 
indicate that unsatisfactory metabolic control, long 
DM1 duration, low pubertal stage (especially in newly 
diagnosed patients), high daily insulin dose [5–7], low 
body mass index, reduced renal function, and the 
presence of diabetic complications are clinical factors 
of increased risk of decreased bone status or reduced 
bone mineral density (BMD) [8]. Nonetheless, the 
outcomes of studies are ambiguous, and other authors 
disclaim any influence of metabolic control, disease 
duration, and insulin requirement on BMD [9, 10], 
or they suggest that the impact of diabetes-specific 
parameters on bone mineral density is low [11, 12]. 
Interestingly, bone status assessment in subjects hav-
ing T1D for 50 or more years showed normal results, 
and the fracture risk among patients was comparable 
to non-diabetic peers [13].
The gold standard for diagnosing changes in bone 
is two-dimensional X-ray absorptiometry (DXA). Al-
though it is a widely used technique and is best for pre-
cise assessment, its application for screening purposes 
in the paediatric population is a point of argument, 
mainly due to the exposure to X-ray radiation [14, 15].
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control, and history of acute diabetes complications had 
no impact on bone quality.
This study aimed to reassess the bone status of pa-
tients with T1D and compare results with those were 
obtained 10 years earlier, as well as to estimate the 
impact of diabetes-related parameters on bone
Material and methods
Patients
During the initial study — 10 years earlier — 182 children and 
adolescents with T1D were examined [6]. Based on the last known 
patients’ contact details from the database of the outpatient clinic 
as well as hospital record from the Department of Children’s Dia-
betology in Katowice, Poland, no less than three attempts at tele-
phone contact were made, to invite patients for participation in the 
current study. Additionally, information about the investigation 
was given to diabetology clinics on the territory of Upper Silesia. 
However, many of the contact details from the paediatric diabetes 
centre were out of date, and some of the patients had moved to 
other cities or abroad and could not take part in the examination 
even if various dates for appointments were offered. Ultimately 32 
patients (20 men, 12 women) aged 12.8–27.62 (20.5 ± 3.93) years 
with DM1 lasting 11.3–17.9 (13.9 ± 1.97) years agreed to take part 
and appeared for the examinations. The general characteristics of 
the study group are presented in Table 1.
Quantitative ultrasound (QUS) is a simple, non-in-
vasive, and cost-effective method. More importantly, it 
does not require the use of radiation. These advantages 
could favour its use for bone status investigation in pae-
diatrics, but there are some controversies because it does 
not assess bone structure and geometry separately (pa-
rameters influenced by age, height, and timing of sexual 
maturation). Nonetheless, studies have confirmed the 
utility of phalangeal QUS in the assessment of bone 
status in children, adolescents, and young adults, with 
a very small confounding effect related to bone size, 
as well as in monitoring longitudinal changes [14–17].
In 2007 in the region of Silesia, Poland, two studies 
of bone quality measured by QUS amongst children 
and adolescents with T1D were performed [3, 6]. 
Bone quality of adolescents with T1D was significantly 
worse than that of healthy peers. Moreover, those with 
HbA1c > 7.0% (> 53 mmol/mol) had a significantly lower 
amplitude-dependent speed of sound (Ad-SoS SDS) [3]. 
T1D duration in pre-pubertal children, as well as ado-
lescents, was negatively related to QUS measurement 
outcomes [3, 6]. Gender, long- and short-term metabolic 
Table 1. Characteristics of the study group. Values given as total number (n) and percentage or mean ± standard deviation 
and 95% confidence interval
Gender
All patients Females Males p value  









































































Additional diseases* [Yes/No] 10 (31.3%)/22 (68.7%) 6 (50%)/6 (50%) 4 (20%)/16 (80%) 0.08 (c2)
Fractures [Yes/No] 10 (31.25%)/22 (68.75%) 12 (100%)/0 (0%) 10 (50%)/10 (50%) < 0.01 (c
2)
Additional medication [Yes/No] 10 (31.25%)/22 (68.75%) 5 (41.67%)/7 (58.33%) 5 (25%)/15 (75%) 0.32 (c
2)
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Methods
Clinical data of all of the 32 patients were collected. In the whole 
group, bone status was examined by QUS (using the same device 
as 10 years earlier), and 24 patients also consented for DXA mea-
surements
Clinical data
Data were collected in a compendious, standardised questionnaire. 
They included the history of any bone fractures, medications, and 
comorbidities (those that are known to impact bone health or me-
tabolism were considered as relevant). Patients were also asked to 
give detailed information concerning diabetes: date of diagnosis, 
present daily insulin dose, and the number of severe acute diabetes 
complications in the past year [diabetic ketoacidosis (DKA) and 
severe hypoglycaemia (SH) episodes]. Given the daily insulin dose 
and weight, the daily insulin requirement (DIR) was calculated 
for each patient. Because the group consisted of adolescents and 
young adults, height, weight, and the calculated body mass index 
(BMI) were expressed using the standard deviation score (SDS).
Bone measurements
Quantitative ultrasound measurements [DBM Sonic 1200 device 
(IGEA, Carpi, Italy)] were performed at the distal end of the proxi-
mal phalanges II to V of both hands. A mean of the amplitude-
dependent speed of sound (Ad-SoS) values obtained for all fingers 
of the non-dominant hand was calculated. In order to normalise the 
result for age and gender, an SDS was calculated using a standard 
Z-score transformation with mean value and standard deviation 
appropriate for age and sex group. Normative data for phalan-
geal QUS have been published (17). QUS assessment was done 
by one experienced investigator. For the performed quantitative 
ultrasound measurements, the calculated coefficient of variation 
(CV%) equalled 0.64%.
Bone densitometry (DXA measurements) was carried out through 
Hologic Explorer (Hologic Inc., Waltham, MA, USA; software ver-
sion: 13.0:3). Bone mineral density (BMD [g/cm2]) for total body 
(TB-BMD) and lumbar spine (s-BMD) was estimated. For the 
obtained values, respective SDS values were calculated using 
gender- and age-specific reference data from Hologic Explorer. All 
measurements were performed by the same experienced techni-
cian — the intra-individual precision (CV%) of the measurements 
was 1.8% for TB-BMD and 1.6% for s-BMD.
As described above for the QUS and DXA results, the SDS was 
calculated. The Z-score transformation is necessary to achieve 
a normalisation that allows comparison between children of differ-
ent ages and genders. The narrow normal range of SDS is defined 
as –1.0 to 1.0, and a wide range from –2.0 to 2.0. Based on DXA, if 
there are no clinically significant fractures, “low BMD” should be 
diagnosed when BMD SDS ≤ −2.0 [18].
The study was approved by the Ethics Committee of the Medical 
University of Silesia, Katowice, Poland (SUM NN-6501-95/06), and 
written informed consent was received from participants prior to 
inclusion in the study.
The database can be provided on request.
Statistical analysis
Statistical analyses were performed using R software (http://www.
bioconductor.org/). Descriptive statistics — number (n), median, 
upper and lower quartile (and), minimal (min) and maximal (max) 
value, mean, and standard deviation (SD) — were determined for 
all of the analysed parameters. We used Tukey’s test to identify 
outlying values and the Lilliefors parametric test to assess the 
normality of the distribution. The variance homogeneity hypoth-
esis was tested using a Bartlett statistic. Comparative analysis 
of normally distributed variables was carried out by analysis of 
variance (ANOVA) or Student’s t-test depending on the group 
number. In cases of other types of distribution, the nonparametric 
ANOVA Kruskal-Wallis and Mann-Whitney test were employed. 
Correlations between two continuous variables were assessed us-
ing Pearson’s or Spearman’s correlation coefficients. We applied 
the Wilcoxon signed rank test to assess changes in time. Statistical 
significance was considered at p < 0.05.
Results
General characteristics of the study group
Table 1 presents the characteristics of the study 
group. The most recent HbA1c results were 6.0–12.7% 
(8.04 ± 1.64%) (42–115 mmol/mol), and mean glycated 
haemoglobin from the last year was 6.28–12.63% 
(8.13 ± 1.49%) (45–116 mmol/mol), which allows us 
to consider the patients’ metabolic control as insuf-
ficient. The most recent HbA1c value and the last 
year ’s mean had strong, positive correlation (r = 0.86, 
p < 0.001).
The mean daily insulin requirement was 0.78 ± 0.21 
unit/kg. Twenty-two patients declared to have other 
comorbidities and intake of additional medication. Also, 
22 patients had bone fractures (in most cases forearm 
or wrist, two clavicula fractures, one tibia fracture, one 
metatarsal bone fracture, and one of the orbital bones). 
All fractures reported by the patients were related to 
significant trauma. There were some gender differences 
among the study group. Weight SDS values (0.99 ± 0.71 
vs. 0.25 ± 0.90, p = 0.022) were higher in females but 
BMI SDS values (1.05 ± 0.75 vs. 0.29 ± 0.79, p = 0.011) 
were higher in males. Moreover, the occurrence of frac-
tures was higher among girls than boys (100% vs. 50%, 
p = 0.003). Other parameters did not differ between 
genders or subgroups with and without positive bone 
fracture history.
Age was positively related to weight SDS (r = 0.41, 
p = 0.019) as well as to BMI SDS (r = 0.48, p = 0.006). 
Also, the duration of DM1 was positively associated 
with weight SDS (r = 0.48, p = 0.006) and BMI SDS 
(r = 0.49, p = 0.005). Weight SDS was associated with 
height SDS (r = 0.54, p = 0.001) and BMI SDS (r = 0.81, 
p < 0.001). Surprisingly, we observed also a negative 
correlation of weight SDS as well as BMI SDS and daily 
insulin requirement (r = –0.52, p = 0.003 and r = –0.42, 
p = 0.022, respectively).
QUS measurements
Mean Ad-SoS SDS for the whole study group was 
–0.22 ± 1.25 (95% CI: –0.67, 0.23). Analysis using paired 
tests showed no significant change (mean d Ad-SoS 
SDS –0.13 ± 1.09 [95% CI: –0.53, 0.26]) in Ad-SoS SDS 
between the current and past assessment (–0.09 ± 1.03 
[95% CI: –0.46, 0.28]) (Tab. 2). We revealed a significant 
correlation of the past and present Ad-SoS SDS results 
(r = 0.55, p = 0.001) (Fig. 1), as well as a positive associa-
tion between the current QUS measurement result and 
its change in time — d Ad-SoS SDS (r = 0.62, p < 0.0001). 
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There were no gender differences in the present 
Ad-SoS SDS [female vs. male: –0.71 ± 1.32 (95% CI: 
–1.54, 0.12) vs. 0.07 ± 1.42 (95% CI: –0.46, 0.60), Cohen’s 
d = 0.64 – medium effect size] as well as in the QUS 
measurement results from 10 years earlier (Tab. 2, rank 
biserial correlation coefficient 0.20 — small effect size). 
Nevertheless, the change in time in Ad-SoS SDS (d 
Ad-SoS SDS — the difference between the present value 
and the one measured 10 years earlier) was greater in 
males [0.17 ± 1.00 (95% CI: –0.29, 0.64) vs. –0.65 ± 1.09 
(95% CI: –1.33, 0.04), p = 0.038, Cohen’s d = 0.79 — me-
dium effect size]. We found no relation between Ad-SoS 
SDS and anthropometric parameters.
DXA measurements and their relation to present 
QUS results
The mean TB-BMD SDS in the study group was 
–1.53 ± 0.75 (95% CI: –1.87, –1.19) and s-BMD SDS 
–0.39 ± 0.98 (95% CI: –0,80, 0,02).
TB-BMD SDS was positively associated with age 
(r = 0.54, p = 0.012), weight SDS (r = 0.62, p = 0.003), 
height SDS (r = 0.46, p = 0.036), and BMI SDS (r = 0.47, 
p = 0.032), but we found no correlation between the 
SDS of the anthropometric parameters and s-BMD SDS.
TB-BMD SDS was significantly, positively related 
to s-BMD SDS (r = 0.61, p = 0.003). TB-BMD SDS in-
creased along with d Ad-SoS SDS (r = 0.57, p = 0.021), 
but we could not confirm any association between DXA 
parameters and the present Ad-SoS SDS.
Bone measurements and diabetes-related 
parameters
Glycosylated haemoglobin (HbA1c) values — most 
recent and the mean from the last year — were not 
associated with Ad-SoS SDS or d Ad-SoS SDS. Also, no 
relation of HbA1c values with either TB-BMD SDS or 
s-BMD SDS was found. We also found no associations 
of bone measurement results, regardless of the method 
applied, and either disease duration or DIR. Detailed 
data are presented in Table 3.
Bone measurements, fractures, comorbidities, and 
additional medication
All fractures reported by the patients were non-ver-
tebral and high-energy fractures. Presence of comor-
bidities or history of additional medication did not 
impact the results of the QUS measurement. Also, all 
parameters assessed using DXA were not influenced by 
comorbidities and additional medication.
Discussion
We showed that in our patients, bone status measured 
using QUS did not change during a decade. The past 
and present results were in positive correlation, as 
was the current Ad-SoS SDS and its change in time (d 
Ad-SoS SDS). Both means of the DXA results — total 
body and spine — were significantly decreased. Al-
though the decrease is smaller than 2 SDS, it can be 
considered as clinically relevant.
In our study, QUS outcomes were independent of 
the results of bone assessment using the gold standard 
Table 2. Quantitative ultrasound measurement results during the current study, baseline measured 10 years earlier, and the 
difference — data presented as mean, standard deviation and 95% confidence interval
All patients Females (F) Males (M) F vs. M 
Ad-SoS SDS baseline  
(10 years earlier)
–0.09 ± 1.03 
(–0.46, 0.28)
–0.06 ± 1.04  
(–0,72, 0.59)
–0.10 ± 1.05 
(–0.59, 0.39)
p = 0.276 
Small effect size
Ad-SoS SDS current -0.22 ± 1.25 (–0.67, 0.23)
0.71 ± 1.32 
(–1.54, 0.12)
0.07 ± 1.42 
(–0.46, 0.60)
p = 0.088  
Medium effect size
d Ad-SoS SDS
–0.13 ± 1.09 
(–0.53, 0.26)
0.17 ± 1.00 
(–0.29, 0.64)
–0.65 ± 1.09  
(–1.33, 0.04)
p = 0.038  
Medium effect size
Ad-SoS SDS — amplitude-dependent speed of sound standard deviation score; d Ad-SoS SDS — difference in Ad-SoS SDS between the current and baseline 
measurement
Figure 1. Correlation of present amplitude-dependent speed of 
sound standard deviation score (Ad-SoS SDS) and the quantitative 
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DXA (TB-BMD SDS and s-BMD SDS). However, inter-
estingly, TB-BMD SDS was positively associated with 
the change in time in Ad-SoS SDS (d Ad-SoS SDS). 
Diabetes-related parameters such as glycaemic control, 
DIR, and disease duration did not impact bone status, 
regardless of the method applied. Although among 
our patients fractures were more common in females, 
history of fractures, comorbidities, and additional medi-
cation did not influence the bone measurement results.
The results of studies concerning the relation of 
T1D and bone status are ambiguous. The specific 
pathophysiology of bone disorders in diabetes and the 
correlation between these medical conditions is still 
an open question. One of the most recent publications 
regarding bone diseases in individuals with T1D sug-
gests that it is one of the manifestations of microvascular 
complications [1].
Most studies indicate a negative influence of T1D 
on bone tissue, also in adolescents and young adults [1, 
19–21]. In our research the bone status of the studied 
patients had not deteriorated 10 years after the initial 
examination, although the QUS results obtained at 
baseline in adolescents were lower than those in healthy 
controls (−0.34 [95% CI: −0.57, −0.11] vs. −0.03 [95% 
CI: −0.15, 0.08], p < 0.05) [6]. Although there was a sta-
tistically significant difference, the results were within 
normal ranges, and the results did not deteriorate 
with time. Other authors [8, 9] disclaim the influence 
of diabetes-specific parameters on BMD or affirm that 
their impact is low [11–13, 22]. Vazquez et al. showed 
that children and adolescents with non-complicated 
T1D have no alteration of bone mass, but the physiologi-
cal increase of bone density is smaller than in healthy 
peers. We found no relation between diabetes-related 
parameters and bone status assessed by either of the 
two methods — QUS and DXA. Our previous study, 
contrary to the current observation, showed a signifi-
cant association between HbA1c and the QUS results 
(r = −0.22, p < 0.05) [6]. For both correlations the coef-
ficients were quite similar, with a small effect size, so 
this difference may partially be explained by the diverse 
number of study participants. Moreover, the baseline 
study was carried out during the most dynamic period 
in bone changes, whereas the current measurements 
concerned mostly people in whom skeletal maturation 
should be completed — in this case the impact of gly-
caemic fluctuations might be less pronounced.
We should emphasise that our present and previ-
ous studies examined young people. Publications 
that describe the results of bone measurements in the 
population of adults with long-term type 1 diabetes 
[23, 24] did not confirm any significant differences in 
BMD compared to healthy controls. Maddaloni et al. 
examined a population of aging patients with T1D, 
which lasted 50 years or more (mean HbA1c 7.1%). 
Interestingly, their investigation exhibited low rates 
of non-vertebral fractures, normal results of the DXA 
examination, and a comparable risk of fracture in T1D 
patients compared to non-diabetic peers [13]. Their 
findings, as well as those of some other studies and our 
research, indicate that T1D duration is not a significant 
factor influencing bone status [22, 25].
We measured diabetics’ bone density by quantitative 
ultrasound (QUS) and two-dimensional X-ray absorp-
tiometry (DXA) methods. QUS measurements were 
used in the previous research (10 years ago) because 
the study group consisted of children and youths [6]. 
Outcomes of the ultrasound method are less dependent 
on bone size, patients are not exposed to radiation 
[26], and its results are comparable to those of DXA 
[14]. In this follow-up study, we applied both methods 
[3]. Despite the fact that the obtained QUS and DXA 
results showed, similarly, no significant deterioration 
of skeletal status, we could not confirm any correlation 
between the outcomes. This suggests that, regardless 
of some propositions from other studies [27], these 
methods cannot be used alternatively to assess bone 
status in T1D patients.Our analysis indicates that past 
and present Ad-SoS measurements were significantly 
correlated, as were the present result and d Ad-SoS SDS. 
There were no differences between genders, although 
d Ad-SoS SDS was greater in males, and fractures were 
more common in females. Diabetes-related parameters 
did not affect the bone status or its changes. Salvatoni 
Table 3. Correlations between current results of bone measurements and diabetes-related parameters
Ad-SoS SDS d Ad-SoS SDS TB-BMD SDS s-BMD SDS
HbA1c mean from last year r = –0.17, p = 0.354
s r = –0.15, p = 0.438s r = 0.08, p = 0.711n r = 0.04, p = 0.846n
HbA1c most recent r = –0.17, p = 0.372
s r = -0.14, p = 0.449s r = –0.01, p = 0.977n r = 0.12, p = 0.594s
T1D duration r = –0.21, p = 0.257s r = 0.02, p = 0.908n r = 0.33, p = 0.151m r = –0.04, p = 0.867n
DIR r = 0.01, p = 0.941n r = –0.23, p = 0.219s r = –0.39, p = 0.099m r = –0.18, p = 0.416s
Correlation coefficient and its p value, the effect size is marked, respectively: n — none, s — small, m —medium; Ad-SoS SDS — amplitude-dependent speed of sound 
standard deviation score; d Ad-SoS SDS — difference in Ad-SoS SDS between the current and baseline measurement; HbA1c — haemoglobin A1c; T1D — type 1 
diabetes; DIR — daily insulin requirement; TB-BMD SDS — total body bone mineral density standard deviation score; s-BMD SDS — spine bone mineral density 
standard deviation score
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et al. in their 2-year follow-up study likewise concluded 
that neither metabolic control nor microvascular com-
plications impact the bone status.
We observed increasing weight and BMI SDS with 
age and T1D duration. This is in concordance with 
results obtained by other authors [28]. It is worth under-
lining that this is one of the few follow-up studies that 
compare bone status between adolescence and young 
adulthood in the same group of patients. The main 
limitation of this study is the sample size, the reasons 
for which we described above. There were also no DXA 
measurements performed during the initial assessment, 
and therefore the longitudinal analysis concerns only 
bone status assessed using QUS.
Conclusions
The bone status parameters of the examined patients 
with currently suboptimal glycaemic control were 
found to be lowered in comparison to a normative 
reference population, both at baseline (measured using 
QUS) and follow-up (QUS and DXA measurements), 
although no further deterioration was observed during 
the 10-year follow-up period. Glycaemic control was 
currently suboptimal in the studied group and did not 
influence bone status examined by either of the meth-
ods. Therefore, it seems, that potential changes in bone 
in T1D develop very slowly and are not directly related 
to glycaemic control. 
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